Physician profile
Seth D Fox
NPI 1669766481
$9,363.09
in general payments reported to CMS, 2019-2025
28 companies · $728 in 2025
The $728 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,391 · 2020: $421 · 2021: $1,324 · 2022: $1,812 · 2023: $1,262 · 2024: $1,425 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,849.43 | 2019-2024 | Tecnis Iol |
| New World Medical,INC. | $1,634.90 | 2019-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Alcon Vision LLC | $1,100.50 | 2019-2025 | Clareon, Centurion, Argos |
| Bausch & Lomb Americas INC. | $1,000.47 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Allergan, INC. | $838.20 | 2019-2022 | |
| Abbvie INC. | $632.78 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $413.37 | 2021-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $343.21 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $311.09 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $201.01 | 2019-2021 | |
| Biotissue Holdings INC. | $135.88 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $132.70 | 2021-2024 | Acthar |
| Oyster Point Pharma, INC. | $124.57 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $124.28 | 2019 | |
| Dompe US, INC. | $87.07 | 2020-2025 | Oxervate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $63.41 | 2019-2021 | |
| Ocular Therapeutix, INC. | $57.29 | 2022-2025 | Dextenza |
| Sight Sciences, INC. | $54.07 | 2022-2024 | Omni Surgical System |
| Horizon Therapeutics Plc | $42.83 | 2022-2023 | Tepezza |
| Ivantis, INC | $38.54 | 2021 | |
| Rxsight INC | $31.91 | 2022 | |
| Carl Zeiss Meditec, INC. | $29.71 | 2021 | |
| Glaukos Corporation | $27.31 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Harrow Eye, LLC | $23.71 | 2024 | Vevye |
| Amgen INC. | $19.07 | 2024 | Tepezza |
| Omeros Corporation | $18.01 | 2019 | |
| Thea Pharma INC. | $16.02 | 2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.